

31 **ABSTRACT**

32 **Background:** Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex disease
33 characterized by multiple inflammatory endotypes. Although recent progress has been
34 made in endotype-based classification, developing tailored therapeutic strategies for
35 CRSwNP remains challenging. This study aimed to optimize therapeutic outcomes in
36 CRSwNP by identifying potential molecular markers.

37 **Methods:** We utilized an integrated approach that combined bulk and single-cell RNA
38 sequencing (scRNA-seq) to delineate the molecular signatures inherent to the cellular
39 components of nasal polyp (NP) tissue. The levels of C11-BODIPY (as a marker of lipid
40 peroxidation) and *SLC27A2/FATP2* were assessed using quantitative PCR and
41 immunofluorescence (IF) staining. The effects of lipofermata, a FATP2 inhibitor, were
42 examined in air-liquid interface (ALI) cultured epithelial cells derived from CRSwNP
43 patients and healthy controls.

44 **Results:** Deconvolution analysis of NP tissue revealed an upregulation of genes
45 associated with lipid metabolism in the NP epithelium. In CRSwNP patients, we observed
46 a significant increase in lipid peroxidation and *SLC27A2/FATP2* expression in the NP
47 epithelium. A marked expression of genes critical to metabolic pathways involved in lipid
48 peroxidation was identified in *SLC27A2*-positive epithelial cells. Additionally, FATP2 and
49 lipid peroxidation staining patterns exhibited a positive correlation in their respective %
50 Area levels. Elevated *SLC27A2* expression was associated with disease pathogenesis
51 and correlated with disease severity. Treatment with lipofermata resulted in decreased
52 mRNA levels of *ALOX15*, a key mediator of inflammation and lipid peroxidation, and
53 *FOXJ1*, a marker of abnormal ciliogenesis.

54 **Conclusion:** Elevated *SLC27A2* expression in the NP epithelium correlates with the
55 severity of CRSwNP, highlighting its potential as a therapeutic target for managing
56 advanced CRSwNP cases.

57

58 **Keywords**

59 Chronic rhinosinusitis with nasal polyps (CRSwNP), FATP2 inhibitor, Lipid peroxidation,
60 *SLC27A2* expression, Transcriptomics

61 1. INTRODUCTION

62 Chronic rhinosinusitis (CRS) is a prevalent disease affecting up to 11% and 12% of the
63 population in Europe, South Korea, and the United States, respectively, significantly
64 impairing quality of life by presenting symptoms such as nasal congestion, discharge,
65 facial pressure, anosmia, cough, and fatigue¹⁻³ CRS is traditionally classified into two
66 distinct phenotypes: chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic
67 rhinosinusitis without nasal polyps (CRSsNP).² The endotypes of CRSwNP are
68 determined by the type of inflammation present, including eosinophilic CRSwNP
69 (ECRSwNP; type 2), and non-eosinophilic CRSwNP (nECRSwNP; non-type 2).^{3,4} Type 2
70 CRSwNP is predominant in Western populations, accounting for 80% of cases, while in
71 Asian countries like Korea, Japan, and China, types 1 and 3 are more prevalent,
72 constituting 20–60% of CRSwNP cases.⁴⁻⁷ Recent evidence has elucidated the complex
73 interplay between various inflammatory pathways and tissue remodeling factors,
74 delineating their relevance to the endotypes of CRSwNP.⁸ This growing understanding
75 underscores the importance of a personalized, endotype-targeted approach to the
76 management of CRSwNP.^{3,9} Despite these advances, however, the selection of an
77 optimal therapeutic strategy for CRSwNP remains fraught with challenges, particularly
78 due to the paucity of molecular biomarkers that adequately reflect the clinical
79 characteristics of the various CRSwNP types. Moreover, the existence of cases with
80 mixed or indistinct endotype-specific features exacerbates the intricacy of treatment
81 decision-making.^{7,9-13} Consequently, CRSwNP remains a significant clinical conundrum
82 in the quest for effective, customized therapeutic interventions.

83 Recent advances in genomic profiling have shed light on the pathogenesis of CRSwNP,
84 providing potential solutions to the challenges faced by affected individuals. Whole-
85 transcriptome sequencing has revealed gene signatures linked to inflammation and
86 abnormal host defense mechanisms, as well as distinct transcriptomic differences
87 between ECRSwNP and nECRSwNP.¹⁴⁻¹⁶ Single-cell transcriptome profiling has further
88 enriched our understanding by revealing the complex cellular landscape within NP tissue,
89 identifying subpopulations of immune and epithelial cells that contribute to type 2
90 immunity through the expression of pro-inflammatory mediators.^{14,17-22} Imbalances in
91 cellular populations, such as basal cell hyperplasia and the loss of ciliated/secretory cells,

92 have also been documented.^{17,21}

93 Recent focus has turned to the role of lipid and fatty acid metabolic dysregulation in the
94 pathogenesis of CRSwNP.¹⁹⁻²² *ALOX15*, a lipid mediator implicated in inflammation, has
95 been observed in select subpopulations of macrophages and dendritic cells. Additionally,
96 discernible expression of lipid transport-related genes—*PLTP*, *APOE*, *ABCA1*, and
97 *LRP1*—has been identified within specific subunits of macrophages.²¹ Dysregulated fatty
98 acid metabolism has been observed in nasal polyp-derived eosinophils.²³ Similarly, T
99 helper 2 cells exhibit an enrichment of genes associated with lipid metabolism.²⁰
100 Imbalances in lipid metabolism can also induce epithelial dysfunction. In tuft cells within
101 the NP epithelium, genes related to the arachidonic acid metabolism pathway, including
102 *PTGS1* and *ALOX5*, have been found to be uniquely enriched.¹⁹ Despite its pro-
103 inflammatory effects, *ALOX15*, a marker of lipid peroxidation, has been previously
104 reported to exhibit robust expression in the NP epithelium.²⁴⁻³¹ Recent findings have
105 highlighted the presence of genes associated with lipid peroxidation in the NP
106 epithelium.³²⁻³⁴ Despite these pivotal studies, our understanding of lipid metabolism in
107 epithelial dysfunction remains incomplete, necessitating further research that
108 encompasses all endotypes.

109 In this study, we aimed to identify molecular markers associated with aberrant epithelial
110 activity that may serve as potential prognostic and therapeutic targets for patients with
111 CRSwNP. We analyzed the cellular composition of NP tissues through deconvolution
112 analysis of bulk and single-cell RNA-seq datasets. Our results demonstrated an increase
113 in the expression of genes related to lipid metabolic processes in the epithelial cells of
114 NPs. We found that fatty acid transporter protein 2 (*FATP2*), a long-chain fatty acid
115 transporter encoded by the solute carrier family 27-member 2 (*SLC27A2*) gene, was
116 significantly upregulated in NP epithelium compared to healthy control epithelium.
117 Patients with high expression of *SLC27A2* exhibited increased mucociliary dysfunction-
118 related transcriptional signature genes and severity scores. Inhibition of *SLC27A2*
119 resulted in decreased expression of epithelial dysfunction-related genes. Our findings
120 suggest that *SLC27A2* may be a novel prognostic and therapeutic target gene for patients
121 with severe CRSwNP.

122 **2. METHODS**

123 **2.1 Patient recruitment**

124 We enrolled adult Korean participants with chronic rhinosinusitis with nasal polyps
125 (CRSwNPs) and healthy controls from the Department of Otorhinolaryngology – Head
126 and Neck Surgery at Asan Medical Center (AMC) between July 2019 and April 2022.
127 Written informed consent was obtained from all subjects before the study's
128 commencement, conducted in accordance with the Declaration of Helsinki. This study
129 received approval from the Asan Medical Center Institutional Review Board (IRB No.
130 2019-0619).

131 For patients with CRSwNPs, nasal polyp (NP) tissues were collected during functional
132 endoscopic sinus surgery, and diagnoses followed the criteria outlined in the 2020
133 European Position Paper on Rhinosinusitis and Nasal Polyps guidelines, which included
134 assessing symptoms, nasal endoscopy findings, and computed tomography (CT)
135 imaging.² Exclusion criteria included patients: 1) below 18 years; 2) with a history of
136 unilateral CRS, antrochoanal polyps, fungal sinusitis, allergic fungal sinusitis, aspirin-
137 exacerbated respiratory disease, cystic fibrosis, or primary ciliary dyskinesia; 3) who are
138 pregnant or immunocompromised; 4) administered decongestants, antibiotics, and
139 systemic/topical corticosteroids over four weeks preceding surgery; and 5) with a history
140 of acute respiratory infection within four weeks prior to surgery.

141 Histopathological examination was performed to rule out fungal sinusitis, allergic fungal
142 sinusitis, cystic fibrosis, or primary ciliary dyskinesia. We also inquired about their history
143 of acute upper and lower respiratory tract reactions to aspirin or nonsteroidal anti-
144 inflammatory drugs to identify aspirin-exacerbated respiratory disease. Additionally, we
145 conducted various assessments, including the Sinonasal Outcome Test (SNOT-22),
146 Lund-Mackay CT scores, Lund-Kennedy endoscopic score, nasal polyp score, and polyp
147 grading according to the Davos classification.^{2,35,36}

148 Control tissue samples were obtained from the middle turbinate (MT) mucosa of patients
149 above 18 years old undergoing septoplasty for nasal obstruction without sinusitis on CT
150 or transsphenoidal approach surgery for non-functioning pituitary tumors without adjacent
151 structure invasion on MRI and sinusitis on CT scan. These control subjects had no history
152 of asthma, upper respiratory infection, or administration of systemic, topical

153 corticosteroids, or antibiotic medications within four weeks before surgery. We determined
154 atopic status by detecting specific IgE antibodies to common inhalant allergens using
155 ImmunoCAP™ tests (Phadia, Uppsala, Sweden), and asthma was diagnosed based on
156 medical history and pulmonary function tests, including spirometry and challenge tests.

157

158 **2.2 Utilization of publicly available data**

159 In this study, we employed various publicly available datasets and databases as follows:
160 Bulk RNA-seq datasets from Peng et al.¹⁶ and Nakayama, T., et al.¹⁴, single-cell RNA-seq
161 datasets from Wang et al.²¹ and Ordovas-Montanes et al.¹⁷, and ATAC-seq data from
162 Ordovas-Montanes et al.¹⁷

163

164 **2.3 Bulk RNA-seq data analysis**

165 For the analysis of bulk RNA-seq data (GSE136825; GSE179269), we mapped the reads
166 to the hg38 genome using STAR version 2.7.1a with default parameters.³⁷ Subsequently,
167 we converted the aligned reads into tag directories using HOMER version 4.11.1.³⁸
168 Quantification of each file was performed utilizing the "analyzeRepeats" script in HOMER.
169 We normalized gene expression levels in each sample by calculating fragments per
170 kilobase of transcript per million mapped reads (FPKM). Differential expression genes
171 (DEGs) were identified through DESeq2 analysis based on raw read counts.³⁹ The
172 "getDifferentialExpression" command in HOMER was applied with criteria for significance
173 defined as an adjusted p-value of < 0.05 , more than a two-fold difference in expression
174 levels, and an average FPKM > 2 . Principal component analysis (PCA) distinctly classified
175 the samples into Healthy and CRSwNP clusters. One Healthy sample, aligning more with
176 the CRSwNP cohort, was recognized, and henceforth omitted from further assessments
177 (GSE179269, Figure S2B).

178

179 **2.4 Single-cell RNA-seq analysis**

180 **2.4.1 Surgical biopsy of nasal polyp tissues**

181 To profile the cellular ecosystem of nasal polyp (NP) tissues, we analyzed publicly
182 available single-cell RNA-seq data (accession number HRA000772).²¹ To ensure
183 compatibility with the publicly available bulk RNA-seq dataset (GSE136825) and to

184 maintain uniformity in disease states and tissue locations, we utilized data from 11
185 samples obtained from surgical biopsies of nasal polyp tissues. These samples
186 encompassed 5 non-ECRSwNP and 6 ECRSwNP patients.

187 For our analysis, we included only cells in which mitochondrial RNA accounted for less
188 than 15% of the total RNA content. We performed data integration and anchoring using
189 the top 10,000 highly variable features identified through the variance-stabilizing
190 transformation method. Subsequently, we conducted uniform manifold approximation and
191 projection (UMAP) analysis and constructed a nearest neighbor graph using the
192 'FindNeighbors' function. To identify cell clusters, we employed the 'FindClusters' function
193 with a resolution parameter set to 0.5. Differential expression analysis was carried out
194 using the 'FindMarkers' and 'FindAllMarkers' functions. Additionally, we assessed the
195 expression levels of genes associated with lipid metabolism across various cell types
196 using the 'AddModuleScore' function, which calculated module scores based on genes
197 related to the GO:0006629 lipid metabolic process.

198

199 **2.4.2 Nasal scrapings**

200 To identify cell populations expressing elevated levels of *SLC27A2*, we utilized previously
201 published single-cell RNA-seq data (Ordovas-Montanes et al.).¹⁷ These data included
202 7,886 cells from the ethmoid sinus of 2 patients with chronic rhinosinusitis with nasal
203 polyps (CRSwNP-NP), 2,031 cells from the inferior turbinate of 4 patients with CRSwNP
204 (CRSwNP-IT), and 6,498 cells from the inferior turbinate of 3 healthy controls (Healthy-
205 IT). We included only those cells in which mitochondrial RNA accounted for less than 20%
206 of the total RNA content. Data integration and anchoring were performed using the top
207 3,500 highly variable features determined by the variance-stabilizing transformation
208 method. Subsequently, we conducted uniform manifold approximation and projection
209 (UMAP) analysis and constructed a nearest neighbor graph using the 'FindNeighbors'
210 function. Cluster identification was achieved using the 'FindClusters' function with a
211 resolution parameter set to 0.5. Differentially expressed genes (DEGs) were identified
212 using the 'FindMarkers' and 'FindAllMarkers' functions. Principal component analysis and
213 clustering were conducted using Seurat version 4.3.0.1 in R version 4.3.0.

214

215 **2.5 Gene ontology analysis**

216 To identify enriched Gene Ontology (GO) terms among the Differentially Expressed
217 Genes (DEGs), we employed Metascape.⁴⁰

218

219 **2.6 Module GSEA scores**

220 For the assessment of variation in predefined gene sets across samples within our
221 microarray expression datasets, we utilized Gene Set Variation Analysis (GSEA),
222 specifically version 1.48.2, an open-source software available through R/Bioconductor.⁴¹
223 GSEA provides a non-parametric and unsupervised method for this purpose. The GSEA
224 scores for each sample were calculated using the FPKM gene expression matrix of the
225 selected gene set, and this computation was carried out using the GSEA package in R
226 version 4.3.0.

227

228 **2.7 Immunofluorescence**

229 The samples (refer to Table 1) were fixed in 4% paraformaldehyde in phosphate-buffered
230 saline (PBS) and subsequently embedded in paraffin using standard procedures.
231 Sections of the specimens, each 4- μ m in thickness, were subjected to heat-induced
232 antigen retrieval by boiling in 10 mM citrate buffer (pH 6.0) and allowed to cool to room
233 temperature for 20 minutes. The specimens were then incubated overnight at 4°C with
234 anti-FATP2 (14048-1-AP, Proteintech, IL, USA; 1:100) antibodies. Afterward, the
235 specimens were incubated with goat anti-rabbit Alexa Fluor 488 (A11008, Invitrogen, OR,
236 USA; 1:200) and BODIPY™ 581/591 C11 (D3861, Invitrogen, OR, USA; 10 μ M) for 2
237 hours at room temperature. Finally, the sections were counterstained with DAPI (D1306,
238 Invitrogen, OR, USA; 1:1000) and examined using a confocal laser microscope (LSM 900,
239 Carl Zeiss, Germany). Image analysis and quantification were performed using ImageJ
240 version 1.53k.

241

242 **2.8 Oil Red O (ORO) staining**

243 To assess lipid droplets in the tissue, we employed Oil Red O (ORO) staining. Fixed
244 frozen tissue samples (see Table 1) were rinsed with 60% isopropanol for 2 minutes,
245 followed by staining with a freshly prepared ORO working solution (Sigma-Aldrich,

246 Catalogue #O1391) for 15 minutes. After staining, the sections were rinsed three times
247 with 60% isopropanol (1 minute each) and twice with distilled water. Subsequently,
248 sections were counterstained with 30% modified Mayer's hematoxylin for 30 seconds,
249 rinsed with tap water and two changes of distilled water, and finally, mounted in aqueous
250 mounting media (Aquatex®, Sigma-Aldrich).

251

252 **2.9 Quantitative real-time PCR**

253 Total RNA was extracted from whole-tissue and epithelial cells of CRSwNPs and healthy
254 controls (see Table 1) using the RNeasy Mini kit (QIAGEN). Reverse transcription was
255 carried out using 500 ng of total RNA with the RevertAid First Strand cDNA Synthesis kit
256 (Thermo Fisher Scientific). Real-time quantitative PCR (qPCR) was performed with
257 TOPreal qPCR 2X PreMIX (SYBR Green with low ROX; No. RT500M; Enzynomics Co.
258 Ltd., Daejeon, Korea). The qPCR conditions included an initial cycle at 95°C for 10
259 minutes, followed by 50 cycles of 10 seconds at 95°C for denaturation, 15 seconds at
260 60°C for annealing, and 20 seconds at 72°C for extension. A melting program was
261 executed at 72–95°C with a heating rate of 1°C/45 seconds. The Rotor-Gene Q v. 2.3.1
262 (Qiagen, Hilden, Germany) was utilized to capture and analyze spectral data.

263

264 **2.10 ATAC-seq analysis**

265 For ATAC-seq analysis, sequenced reads were aligned to the human genome reference
266 (GRCh38/hg38 assembly) using Bowtie2 version 2.3.4.1 with default parameters, and
267 clonal reads were excluded from further analysis.⁴² A minimum of 10 million uniquely
268 mapped reads was obtained for each condition. To identify peaks of ATAC-seq enrichment
269 over the background, we utilized the 'makeTagDirectory' followed by the 'findPeaks'
270 command from HOMER version 4.11.1.³⁸ A false discovery rate (FDR) threshold of 0.001
271 was applied to all datasets. The total number of mapped reads in each sample was
272 normalized to 10 million mapped reads. To visualize the normalized tag density of genes,
273 we used the Integrative Genomics Viewer.

274

275 **2.11 Air-liquid interface (ALI) culture**

276 Primary human nasal epithelial cells (HNECs) were isolated from either polyp or control

277 tissues (see Table 1). Passage-2 HNECs (1.5×10^5 cells/well) were seeded in 0.25 mL
278 of culture medium on Transwell clear culture inserts (12 mm, with a 0.4 μm pore size;
279 Costar; Corning Inc., Corning, NY). Initially, cells were cultured in a 1:1 mixture of basal
280 epithelial growth medium and Dulbecco's modified Eagle's medium containing previously
281 described supplements in a submerged state for the first 7–9 days. Upon reaching
282 confluence, the apical medium was removed to establish an ALI, and thereafter, the
283 medium was replenished only in the basal compartment. RNA was extracted from HNECs
284 on day 14 following ALI establishment.^{43,44}

285

286 **2.12 In vitro lipofermata treatment**

287 At day 14 of ALI culture, HNECs were exposed to either dimethyl sulfoxide (DMSO;
288 SIGMA, 276855-100ML) or 2 μM lipofermata (MedChemExpress, HY-116788), a
289 *SLC27A2/FATP2* inhibitor, in the apical compartment for 24 hours. RNA was subsequently
290 extracted from HNECs.

291

292 **2.13 Statistical analysis**

293 Unless otherwise specified, statistical analyses were performed using GraphPad Prism
294 version 9 (GraphPad Software, La Jolla, CA, USA). Data are presented as mean \pm
295 standard error (SEM), unless otherwise stated in each figure legend. When applicable,
296 two-tailed unpaired t-tests, paired t-tests, ordinary one-way ANOVA, and Wilcoxon
297 signed-rank tests were employed. In all statistical analyses, similar expected variances
298 were assumed between compared groups, and significance was accepted at the 95%
299 confidence level (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ for two-tailed unpaired t-tests, paired
300 t-tests, and ordinary one-way ANOVA; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ for Wilcoxon
301 signed-rank tests).

302 3. RESULTS

303 3.1 Dissecting the nasal polyp transcriptome reveals altered lipid metabolism

304 To unveil unique molecular signatures within distinct cell types of NP tissues from
305 CRSwNP patients, we employed a comprehensive transcriptomic approach, utilizing both
306 bulk RNA-seq and scRNA-seq datasets. To enhance statistical robustness, we
307 incorporated a publicly available bulk RNA-seq dataset (GSE136825; 28 Healthy, 42
308 CRSwNP).¹⁶ Additionally, we adopted a quality-assured public scRNA-seq dataset
309 (HRA000772; 11 CRSwNP)²¹ to capture cell-type-specific molecular nuances (Figure 1A).
310 Comparative analysis of the GSE136825 dataset revealed 971 differentially expressed
311 genes (DEGs) between the 28 healthy and 42 CRSwNP samples. Among these DEGs,
312 552 were upregulated, and 419 were downregulated in CRSwNP (Figure S1A).
313 Subsequent GO analysis shed light on potential molecular pathways and biological
314 implications of these DEGs. Upregulated genes in CRSwNP were associated with GO
315 terms such as 'inflammatory response,' 'innate immune response,' 'cellular response to
316 lipid,' and 'superoxide metabolic process,' while downregulated genes were linked to
317 'circulatory system process,' 'response to hormone,' and 'salivary secretion' (Figure S1B).
318 Using uniform manifold approximation and projection (UMAP), we identified eight distinct
319 cell clusters encompassing 72,032 cells in the HRA000772 dataset. These clusters
320 comprised epithelial cells, NK/T cells, B cells, myeloid cells, fibroblasts, endothelial cells,
321 vascular smooth muscle cells (VSMCs), and cycling cells (Figure S1C). Cluster-specific
322 marker genes were employed to delineate these cell types (Figure S1D).

323 Subsequent integrated transcriptome analysis highlighted genes predominantly
324 expressed in each cell type, with a particular focus on those upregulated in CRSwNP
325 patients. These included 45 genes in epithelial cells, 15 in NK/T cells, 7 in B cells, 86 in
326 myeloid cells, 23 in fibroblasts, 5 in endothelial cells, 6 in VSMCs, and 19 in cycling cells
327 (Figure 1B, left). A subsequent GO analysis unveiled specific functional themes for these
328 genes, elucidating characteristic GO terms for each cell type, such as 'interleukin-4 and
329 interleukin-13 signaling,' 'long-chain fatty acid metabolic process,' and 'lipid modification'
330 for epithelial cells, and 'signaling by ROBO receptors' for NK/T cells, among others (Figure
331 1B, right). Most of these GO terms aligned with established associations for each cell type
332 in NP tissues. However, we gave priority to those GO terms with roles yet to be fully

333 defined. Notably, lipid metabolism-linked GO terms featured prominently in the GO
334 analysis of both whole tissues and specific cell types, especially epithelial and myeloid
335 cells (Figure 1B). While previous studies have highlighted lipid metabolic processes in
336 dendritic cells, macrophages, and Th2 cells^{20,21}, their role in the NP epithelium remains
337 an active area of investigation.

338 In our effort to comprehend the complex cellular milieu of nasal polyps, we first
339 addressed potential analytical biases. Our primary objective was to identify genes
340 associated with lipid metabolic pathways that exhibited elevated expression in CRSwNP
341 patients. Through meticulous transcriptome analysis at the tissue level, we identified a
342 set of 38 genes with increased expression in nasal polyp samples (refer to Figure S1E).
343 Interestingly, pivotal genes such as *ALOX5*, *ALOX5AP*, *AOAH*, *APOE*, *PLA2G7*, and
344 *TREM2* demonstrated marked upregulation in CRSwNP subjects compared to their
345 healthy counterparts (Figure 1C). These genes were intricately linked to molecular
346 processes and biological activities, particularly those related to inflammatory responses,
347 arachidonic acid and eicosanoid metabolism, and lipid oxidation processes (Figure 1D).
348 A deeper dive into the module scores of these 38 genes associated with lipid metabolic
349 pathways revealed pronounced scores, primarily in myeloid, epithelial, and NK/T cells.
350 Notably, epithelial cells exhibited an elevated module score, surpassed only by myeloid
351 cells (Figures 1E and 1F). Our findings shed light on perturbed lipid metabolism in nasal
352 polyp tissue, suggesting that these upregulated genes may be intricately involved in
353 epithelial anomalies and heightened inflammatory events.

354 355 **3.2 Augmented lipid peroxidation in nasal polyp epithelium of CRSwNP patients**

356 To explore the potential association between lipid metabolic perturbations and atypical
357 NP epithelium in CRSwNP patients, we correlated genes associated with lipid metabolic
358 processes (38 genes) with those expressed in epithelial cells (45 genes). This alignment
359 yielded 6 pertinent genes (Figure 2A). There was a marked difference in the mRNA
360 expression levels of *ALOX15*, *GSTP1*, *IMPA2*, *SAA1*, *SGPP2*, and *SLC27A2* between
361 the healthy and CRSwNP groups (Figure 2B). Furthermore, these genes exhibited robust
362 expression in epithelial cell (Figure 2C and S2A). To reinforce our findings' statistical
363 robustness, we incorporated an external public bulk RNA-seq dataset (GSE179269; 7

364 Healthy, 17 CRSwNP; Figure S2B).¹⁴ In our exploration, CRSwNP patients had 1,290
365 upregulated genes and 580 downregulated genes. Significantly, of our identified 6 genes,
366 *ALOX15*, *IMPA2*, *SGPP2*, and *SLC27A2* were conspicuously elevated in CRSwNP
367 (Figure S2C and S2D). This skewed gene expression hints at disturbances in lipid
368 metabolic processes, possibly pointing to lipid peroxidation and accumulation
369 anomalies.^{26,31,45-47}

370 Extending our preliminary assessments, we examined lipid accumulation and lipid
371 peroxidation in NP tissues of both healthy controls and CRSwNP patients using Oil Red
372 O (ORO) staining and C11-BODIPY (Figure S2E and Figure 2D). As illustrated in Figure
373 1D, CRSwNP patients exhibited a pronounced increase in lipid peroxidation relative to
374 the healthy group (Figure 2D and 2E). Our data underscores the likelihood of upregulated
375 genes involved in lipid metabolic dysfunctions in the NP epithelium, which might amplify
376 epithelial irregularities, partially instigated by intensified lipid peroxidation.

377

378 **3.3 Enhanced *SLC27A2*/FATP2 expression in nasal polyp epithelium**

379 Fatty acid transporters play a critical role in lipid metabolism regulation. Disruption in their
380 expression can significantly affect lipid homeostasis, possibly leading to various cellular
381 abnormalities and diseases.⁴⁸⁻⁵¹ Among the identified candidate genes, *SLC27A2*
382 encodes for FATP2, a fatty acid transporter. Beyond *SLC27A2*, we assessed mRNA levels
383 of other related genes including the solute carrier 27A (*SLC27A*) gene family, fatty acid
384 binding proteins (FABPs), and CD36, contrasting their expressions between healthy
385 individuals and CRSwNP patients. Notably, of the 16 genes examined, only *SLC27A2*
386 exhibited a pronounced elevation in expression in CRSwNP (Figure 2B, 3A, S3A, and
387 S3B). RT-qPCR validation further confirmed the marked difference in *SLC27A2* mRNA
388 expression levels (Figure 3B). We subsequently investigated whether the alterations in
389 *SLC27A2* expression were evident in nasal scrapings as well as in whole tissues.¹⁷ Cells
390 expressing *SLC27A2* were notably present in epithelial cell clusters derived from
391 CRSwNP nasal polyps (Figure 3C and 3D). In alignment with this, FATP2 levels were
392 notably elevated in the NP epithelium of CRSwNP patients when compared to healthy
393 controls (Figure 3E and 3F).

394 Persistent chronic inflammatory stimuli can result in dynamic shifts in chromatin

395 accessibility across all cellular types, inclusive of epithelial cells.^{17,52-55} Consequently,
396 utilizing Omni-ATAC-seq data,¹⁷ we aimed to identify variations in the *cis*-regulatory
397 components of genes implicated in lipid metabolic pathways, notably *SLC27A2*, within
398 epithelial cells from nasal polyps. We observed increased chromatin accessibility in
399 promoters and introns of genes linked to lipid metabolic processes (Figures 3G and S3C).
400 Yet, However, these alterations exhibited no discernible differences among the endotypes
401 of CRSwNP. A parallel analysis failed to discern notable differences in mRNA and protein
402 expressions between ECRSwNP and nECRSwNP (Figures S3D, S3E, and S3F). Lipid
403 peroxidation levels appeared consistent across both groups (Figures S3E and S3G). This
404 observation was substantiated further by an external scRNA-seq dataset (HRA000772)²¹
405 incorporated in our research (Figures S3H, S3I, and S3J). Collectively, our findings
406 indicate an elevated expression of *SLC27A2* in the epithelial cells of CRSwNP patients,
407 irrespective of the endotype, possibly suggesting an epigenetic memory imprint.

408

409 **3.4 Transcriptomic signatures and elevated lipid peroxidation in *SLC27A2*-positive** 410 **nasal polyp epithelial cells**

411 To elucidate the distinct molecular signature of *SLC27A2*-positive (*SLC27A2*⁺) cells in
412 the NP epithelium, we employed the scRNA-seq dataset²¹ used for integrated
413 transcriptome analysis (Figure 1). We isolated the epithelial cell cluster, subsequently
414 dividing it into seven subtypes (Figure 4A). Each cluster-specific gene list identified the
415 cell types of these subtypes (Figure S4A).

416 Using a demarcation of 0 for *SLC27A2* expression, we classified epithelial cells into
417 *SLC27A2*-negative (*SLC27A2*⁻) and those with an expression above 0 as *SLC27A2*⁺
418 (Figure 4B). Notably, the *SLC27A2*⁺ cells constituted 30.18% of the NP epithelium, with
419 a predominance in the Goblet cell, Basal cell, Ciliated cell, and Secretory cell subtypes
420 (Figure S4B). The distribution of *SLC27A2*⁺ cells showed a marked presence in Goblet
421 cell (43.10%) and Ciliated cell (13.76%) compared to *SLC27A2*⁻ cells (Goblet cell, 19.24%;
422 Ciliated cell, 5.06%) (Figure S4C). Among the epithelial subtypes, the Ciliated cell
423 exhibited the highest *SLC27A2* expression (Figure 4C).

424 Distinct gene expression patterns emerged between the two groups. Genes *ALOX15*,
425 *NOS2*, *CST1*, and *DUOX1* consistently showed increased expression in *SLC27A2*⁺ cells,

426 while *RPS27A*, *NFIB*, *IL33*, *KRT5*, and *TP63* were more expressed in *SLC27A2*- cells
427 (Figure 4D). Gene Ontology (GO) analysis revealed unique transcriptomic features: the
428 *SLC27A2*⁺ group showed increased genes linked to ciliopathies, MHC protein complex
429 assembly, fatty acid metabolism, and oxidative phosphorylation, whereas the *SLC27A2*-
430 group was enriched in genes related to cytokine signaling and immune response
431 activation (Figure 4E).

432 In the cohort expressing *SLC27A2*, an elevated transcriptional response was observed,
433 notably for genes involved in reactive oxygen species (ROS) metabolism and lipid
434 oxidation upregulation (Figure S4D). Key enzymes like *ACSL4*, *LPCAT3*, *ALOX15*, and
435 *POR*, pivotal for lipid peroxidation initiation, in conjunction with *FATP2*, showed marked
436 expression disparities (Figure 4F).^{26-29,31,56} Immunofluorescence (IF) analysis revealed a
437 concurrent localization between *FATP2* and lipid peroxidation markers (Figure 4G).
438 Additionally, a direct association was detected between *FATP2* coverage area and lipid
439 peroxidation extent (Figure 4H). This data underscores that, contrasting the heightened
440 immune activity in *SLC27A2*-negative cells, the *SLC27A2*-positive subset, potentially
441 linked to mucociliary clearance anomalies, manifests amplified lipid peroxidation events.
442

443 **3.5 Differential transcriptomic characteristics of *SLC27A2*^{High} CRSwNP**

444 To decipher the transcriptomic distinctions of CRSwNP patients with elevated *SLC27A2*
445 expression, we analyzed the cohort from the GSE136825 study (n = 42, shown in Figure
446 1), applying a cutoff average value ($\log_2\text{FPKM} = 4.18$) to categorize subjects into
447 '*SLC27A2*^{Low} CRSwNP' and '*SLC27A2*^{High} CRSwNP' groups (Figure 5A). A group of 21
448 healthy individuals provided a baseline for comparison. Profiling of gene expression
449 delineated three distinct transcriptomic clusters, with 2,317 genes exhibiting differential
450 expression among the groups. The '*SLC27A2*^{High} CRSwNP' group (Cluster 1) manifested
451 a significant differential expression of 844 genes. A further 661 genes were co-
452 upregulated in both the '*SLC27A2*^{Low}' and '*SLC27A2*^{High}' CRSwNP clusters (Cluster 2),
453 and 812 genes were observed to be downregulated in CRSwNP relative to the healthy
454 control group (Cluster 3), as explicated in Figure 5B.

455 Subsequent GO analysis provided insight into the functional characteristics of the
456 identified clusters. Cluster 1 was characterized by genes involved in ciliopathies,

457 biological oxidation, mucociliary clearance, and arachidonic acid metabolism. The GO
458 terms of Cluster 2 underscored genes linked to the inflammatory response and immune
459 system pathways, emblematic of CRSwNP's inflammatory profile. In stark contrast,
460 Cluster 3 was defined by genes associated with salivary secretion and the regulation of
461 epithelial cell proliferation (Figure 5C). Genes corresponding to pivotal GO terms within
462 each cluster were identified. To corroborate these insights, we cross-validated the gene
463 signatures against an RNA-seq dataset from an independent cohort (GSE179269),
464 detailed in Supplementary Figures 2 and 3.

465 Notably, Cluster 1, encompassing *SLC27A2*, included key genes such as *ALOX15*,
466 which plays a role in inflammation and lipid peroxidation,^{24,26-31} as well as *DUOX1* and
467 *POR*, essential for lipid peroxidation and the escalation of ROS.^{57,58} This cluster also
468 contained *CCL15*, *IL5RA*, and *NOS2*, which are associated with airway inflammatory
469 responses,⁵⁹⁻⁶² alongside *FOXJ1* and *TP73*, identified as markers for atypical ciliary
470 morphology and ciliogenesis (Figure 5D and S5A).⁶³ Conversely, the signature genes of
471 Cluster 2 included *CCL24*, *IL4R*, and *POSTN* (Figure S5B), whereas Cluster 3 was
472 characterized by the expression of *GJC3*, *LYZ*, and *STATH* (Figure S5C). These findings
473 articulate the distinct transcriptomic signatures of *SLC27A2*^{High} CRSwNP patients,
474 emphasizing the profound roles of lipid peroxidation, ciliopathies, and inflammation in the
475 pathology of the disease, offering a window into the molecular heterogeneity underlying
476 CRSwNP.

477

478 **3.6 Correlation between increased *SLC27A2* expression and CRSwNP severity**

479 Investigating the correlation between *SLC27A2* expression and the severity of CRSwNP,
480 we categorized patients from our cohort (outlined in Table 1) into two groups based on
481 *SLC27A2* mRNA expression: '*SLC27A2*^{Low} CRSwNP', encompassing 10 patients with
482 lower expression levels, and '*SLC27A2*^{High} CRSwNP', including 10 patients with higher
483 expression. Clinical assessments utilizing the Lund-Mackay CT score, Lund-Kennedy
484 endoscopic score, nasal polyp score, and polyp grade consistently demonstrated
485 elevated indices in the '*SLC27A2*^{High} CRSwNP' group (Figure 6A). Furthermore, a
486 pronounced correlation emerged between elevated *SLC27A2* mRNA expression and
487 increased levels of CRSwNP pathogenesis markers including *ALOX15*, *FOXJ1*, and

488 *TP73*, primarily in the '*SLC27A2*^{High} CRSwNP' group (Figure 6B and Figure S6A).

489 Extending our investigation, an in vitro air-liquid interface (ALI) culture model of nasal
490 epithelial cells was employed to discern the effect of *SLC27A2* inhibition on disease
491 severity. Nasal epithelial cells derived from four healthy individuals and four CRSwNP
492 patients were subjected to ALI culture. Following treatment with DMSO or 2 μ M
493 lipofermata, a *SLC27A2*/*FATP2* inhibitor, we assessed the expression levels of
494 pathogenesis-related markers *via* RT-qPCR (Figure 6C). Lipofermata treatment resulted
495 in a significant reduction of *SLC27A2* expression in both normal and CRSwNP-derived
496 epithelial cells (Figure 6D). Notably, *ALOX15* mRNA levels, associated with inflammatory
497 processes, were significantly reduced in CRSwNP cells, while they remained unaffected
498 in cells from healthy controls. Additionally, lipofermata treatment effectively decreased the
499 expression of *FOXJ1*, a marker of dysregulated ciliogenesis. While the decrease in *TP73*
500 expression observed did not reach statistical significance ($P = 0.057$), a trend towards
501 downregulation was evident (Figure 6D).

502 These results collectively indicate that elevated *SLC27A2* expression correlates with
503 increased CRSwNP severity, suggesting its utility as a diagnostic biomarker and its
504 potential as a target for therapeutic intervention in severe manifestations of CRSwNP.

505 4. DISCUSSION

506 CRSwNP is a condition characterized by a complex interplay of inflammatory processes.
507 While it has traditionally been associated with eosinophilia and an increased presence of
508 type 2 inflammatory markers, such as IL-4, IL-5, and IgE, recent insights have broadened
509 our understanding of the pathophysiology of CRSwNP. Notably, the disease exhibits a
510 heterogeneous profile, including not only type 2 but also type 1 (IFN- γ , IL-12) and type 3
511 (IL-17, IL-22) inflammatory biomarkers. This complexity is further highlighted by the
512 identification of various endotypes, including mixed and unclassifiable forms, which
513 contribute to the diverse clinical manifestations observed in CRSwNP patients.^{9,13}
514 Histological examinations provide additional evidence of this heterogeneity, revealing that
515 up to 40% of CRSwNP patients display a spectrum of infiltrative patterns, encompassing
516 neutrophilic, mixed eosinophilic-neutrophilic, and paucigranulocytic types. These findings
517 underscore the multifaceted nature of CRSwNP and the need for tailored therapeutic
518 approaches.^{12,64,65}

519 In this study, we undertook a comprehensive analysis of transcriptomic profiles within
520 the cellular landscape of nasal polyp tissue. Utilizing integrated bulk and single-cell RNA
521 sequencing, we discerned a pronounced upregulation of genes associated with lipid
522 metabolism in epithelial and myeloid cell populations within the polyp tissue. This finding
523 resonates with the observed higher incidence of CRS in individuals suffering from
524 metabolic syndrome, reinforcing the hypothesis of metabolic disturbances playing a role
525 in nasal polyposis.^{22,66-69} The enhanced synthesis of prostaglandin D2 (PGD2) in
526 CRSwNP and its metabolite delta-12-PGD2, implicated in the recruitment and activation
527 of type 2 T helper cells and eosinophils, exemplifies this metabolic dysfunction.⁷⁰ Elevated
528 levels of unsaturated fatty acids and uric acid in distinct CRSwNP subtypes are indicative
529 of a metabolic environment that fosters neutrophilic inflammation and a type 2
530 inflammatory response.^{69,71-73} Furthermore, the observed elevation in glucose levels
531 within nasal secretions promotes increased uptake and glycolysis by epithelial cells,
532 accentuating their role in perpetuating inflammation. Our findings articulate the notable
533 overexpression of genes driving lipid peroxidation within the nasal polyp epithelium, which
534 may serve to intensify inflammatory processes and compromise the epithelial barrier,
535 thereby elucidating a mechanistic link between lipid oxidation and CRSwNP

536 pathophysiology.

537 FATP2, a member of the long-chain fatty acid (LCFA)-coenzyme A ligase family encoded
538 by *SLC27A2*, is significantly overexpressed in the NP epithelium of patients with CRSwNP.
539 Such overexpression is implicated in the dysregulation of lipid and fatty acid metabolism,
540 with FATP2 acting as a critical facilitator for the uptake and integration of polyunsaturated
541 fatty acids (PUFAs) into phospholipids, particularly arachidonic acid (AA) and adrenic acid
542 (AdA).⁵⁰ The absence of FATP2 in cells results in reduced levels of arachidonoyl-
543 phosphatidylethanolamine (AA-PE).⁴⁷ This highlights the critical role of FATP2 in
544 synthesizing AA-CoA and AdA-CoA, both essential precursors in the lipid peroxidation
545 pathway.^{46,47,74}

546 Positioned at the nexus of PUFA uptake and conversion, FATP2 operates at the apical
547 membrane and endoplasmic reticulum, facilitating the transformation of AA/AdA into their
548 coenzyme A derivatives.²⁹ This process is complemented by ACSL4 and LPCAT3 within
549 the ER, promoting the activation and incorporation of AA/AdA-CoA into
550 phosphatidylethanolamine (PE). The subsequent enzymatic action of 15-lipoxygenase,
551 encoded by *ALOX15*, along with the contribution of *POR*, leads to an accumulation of
552 lipid hydroperoxides, which precipitates an increase in lipid peroxidation and potential
553 cellular injury.^{29,56} Our investigation revealed elevated expression of the enzymes ACSL4,
554 LPCAT3, *ALOX15*, and *POR* in *SLC27A2*-positive epithelial cells of NP, compared to
555 *SLC27A2*-negative cells. Moreover, co-localization of FATP2 with markers of lipid
556 peroxidation was established, exhibiting a positive correlation in stained area percentages.
557 In concordance, GO terms related to lipid peroxidation and the mRNA levels of key
558 enzymes, including *ALOX15*, *DUOX1*, and *POR*, were significantly higher in NP tissue
559 from patients with high *SLC27A2* expression.

560 While our data suggest a link between FATP2/*SLC27A2* and lipid peroxidation in NP
561 epithelium, the direct contributions of this relationship remain to be fully determined,
562 highlighting an avenue for future research. Notably, the pronounced expression of
563 *SLC27A2* in ciliated cells raises the possibility that the observed loss of these cells in
564 CRSwNP may be attributable to FATP2/*SLC27A2*-mediated lipid peroxidation, presenting
565 an intriguing hypothesis for subsequent exploration.

566 Our analyses reveal a marked expression of genes linked to ciliopathies in *SLC27A2*-

567 positive cells and in patients with high *SLC27A2* expression in CRSwNP. The aberrant
568 expression of these genes is known to contribute to mucociliary dysfunction, which can
569 facilitate the proliferation of pathogenic bacteria and the formation of biofilms, thereby
570 perpetuating a cycle of chronic inflammation. This aligns with prior findings that associate
571 *FOXJ1* and *TP73* with disrupted ciliary structure and functionality in the epithelium of
572 nasal polyps.⁶³ In our cohort, these markers were notably elevated in the group with high
573 *SLC27A2* expression, suggesting a potential mechanistic link between *SLC27A2*
574 overexpression and ciliated cell dysfunction, which may destabilize the epithelial cell
575 environment.

576 Clinically significant disparities were observed between the *SLC27A2*^{High} and
577 *SLC27A2*^{Low} CRSwNP groups across various disease severity scores, including those
578 derived from Lund-Mackay CT and Lund-Kennedy endoscopic assessments.
579 Therapeutically, the targeted inhibition of *SLC27A2/FATP2* using lipofermata attenuated
580 the expression of *ALOX15*, implicated in inflammation and lipid peroxidation, and *FOXJ1*,
581 a marker of ciliary disarray, suggesting the modulation of *SLC27A2* as a viable treatment
582 strategy.

583 In conclusion, our study positions *SLC27A2* as a pivotal biomarker and a potential target
584 for therapeutic intervention in severe CRSwNP. Unbiased transcriptomic profiling has
585 highlighted *FATP2/SLC27A2* as a consistently upregulated entity in CRSwNP,
586 independent of endotypic categorization and intricately associated with lipid peroxidation
587 processes. Inhibition of *SLC27A2* not only resulted in reduced expression of genes
588 central to CRSwNP pathogenesis but also offers a strategic avenue for improving disease
589 prognosis in patients with indeterminate endotypes. These findings advocate for more
590 nuanced patient stratification and personalized treatment approaches, particularly in
591 refractory CRSwNP cases.

592 REFERENCES

- 593 1. Dietz de Loos D, Lourijzen ES, Wildeman MAM, et al. Prevalence of chronic rhinosinusitis in the
594 general population based on sinus radiology and symptomatology. *J Allergy Clin Immunol.*
595 2019;143(3):1207-1214.
- 596 2. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal
597 Polyps 2020. *Rhinology.* 2020;58(Suppl S29):1-464.
- 598 3. Bachert C, Marple B, Schlosser RJ, et al. Adult chronic rhinosinusitis. *Nat Rev Dis Primers.*
599 2020;6(1):86.
- 600 4. Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis:
601 Focus on nasal polyposis. *J Allergy Clin Immunol.* 2015;136(6):1431-1440.
- 602 5. Zhang Y, Gevaert E, Lou H, et al. Chronic rhinosinusitis in Asia. *J Allergy Clin Immunol.*
603 2017;140(5):1230-1239.
- 604 6. Wang X, Zhang N, Bo M, et al. Diversity of T(H) cytokine profiles in patients with chronic
605 rhinosinusitis: A multicenter study in Europe, Asia, and Oceania. *J Allergy Clin Immunol.*
606 2016;138(5):1344-1353.
- 607 7. Kato A, Peters AT, Stevens WW, Schleimer RP, Tan BK, Kern RC. Endotypes of chronic
608 rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment
609 approaches. *Allergy.* 2022;77(3):812-826.
- 610 8. Wang X, Sima Y, Zhao Y, et al. Endotypes of chronic rhinosinusitis based on inflammatory and
611 remodeling factors. *J Allergy Clin Immunol.* 2023;151(2):458-468.
- 612 9. Stevens WW, Peters AT, Tan BK, et al. Associations Between Inflammatory Endotypes and Clinical
613 Presentations in Chronic Rhinosinusitis. *J Allergy Clin Immunol Pract.* 2019;7(8):2812-2820 e2813.
- 614 10. Poposki JA, Klingler AI, Stevens WW, et al. Elevation of activated neutrophils in chronic
615 rhinosinusitis with nasal polyps. *J Allergy Clin Immunol.* 2022;149(5):1666-1674.
- 616 11. Delemarre T, Bochner BS, Simon HU, Bachert C. Rethinking neutrophils and eosinophils in chronic
617 rhinosinusitis. *J Allergy Clin Immunol.* 2021;148(2):327-335.
- 618 12. Delemarre T, Holtappels G, De Ruyck N, et al. A substantial neutrophilic inflammation as regular
619 part of severe type 2 chronic rhinosinusitis with nasal polyps. *J Allergy Clin Immunol.*
620 2021;147(1):179-188 e172.
- 621 13. Xu X, Reitsma S, Wang Y, Fokkens WJ. Highlights in the advances of chronic rhinosinusitis. *Allergy.*
622 2021;76(11):3349-3358.
- 623 14. Nakayama T, Lee IT, Le W, et al. Inflammatory molecular endotypes of nasal polyps derived from
624 Caucasian and Japanese populations. *J Allergy Clin Immunol.* 2021.
- 625 15. Wang W, Gao Z, Wang H, et al. Transcriptome Analysis Reveals Distinct Gene Expression Profiles
626 in Eosinophilic and Noneosinophilic Chronic Rhinosinusitis with Nasal Polyps. *Sci Rep.*
627 2016;6:26604.
- 628 16. Peng Y, Zi XX, Tian TF, et al. Whole-transcriptome sequencing reveals heightened inflammation

- 629 and defective host defence responses in chronic rhinosinusitis with nasal polyps. *Eur Respir J.*
630 2019;54(5).
- 631 17. Ordovas-Montanes J, Dwyer DF, Nyquist SK, et al. Allergic inflammatory memory in human
632 respiratory epithelial progenitor cells. *Nature.* 2018;560(7720):649-654.
- 633 18. Hung LY, Tanaka Y, Herbine K, et al. Cellular context of IL-33 expression dictates impact on anti-
634 helminth immunity. *Sci Immunol.* 2020;5(53).
- 635 19. Kotas ME, Moore CM, Gurrola JG, 2nd, et al. IL-13-programmed airway tuft cells produce PGE₂,
636 which promotes CFTR-dependent mucociliary function. *JCI Insight.* 2022;7(13).
- 637 20. Ma J, Tibbitt CA, Georen SK, et al. Single-cell analysis pinpoints distinct populations of cytotoxic
638 CD4(+) T cells and an IL-10(+)/CD109(+) T(H)2 cell population in nasal polyps. *Sci Immunol.*
639 2021;6(62).
- 640 21. Wang W, Xu Y, Wang L, et al. Single-cell profiling identifies mechanisms of inflammatory
641 heterogeneity in chronic rhinosinusitis. *Nat Immunol.* 2022;23(10):1484-1494.
- 642 22. Tan S, Zhou S, Fan K, et al. Bulk and single-cell transcriptome sequencing reveal the metabolic
643 feature in chronic rhinosinusitis with polyps. *Clin Exp Allergy.* 2023.
- 644 23. Miyata J, Fukunaga K, Kawashima Y, et al. Dysregulated fatty acid metabolism in nasal polyp-
645 derived eosinophils from patients with chronic rhinosinusitis. *Allergy.* 2019;74(6):1113-1124.
- 646 24. Stevens WW, Staudacher AG, Hulse KE, et al. Activation of the 15-lipoxygenase pathway in aspirin-
647 exacerbated respiratory disease. *J Allergy Clin Immunol.* 2021;147(2):600-612.
- 648 25. Kohanski MA, Cohen NA, Barrett NA. Epithelial dysregulation in chronic rhinosinusitis with nasal
649 polyposis (CRSwNP) and aspirin-exacerbated respiratory disease (AERD). *J Allergy Clin Immunol.*
650 2021;148(5):1161-1164.
- 651 26. Ma XH, Liu JH, Liu CY, et al. ALOX15-launched PUFA-phospholipids peroxidation increases the
652 susceptibility of ferroptosis in ischemia-induced myocardial damage. *Signal Transduct Target Ther.*
653 2022;7(1):288.
- 654 27. Hu W, Liang K, Zhu H, Zhao C, Hu H, Yin S. Ferroptosis and Its Role in Chronic Diseases. *Cells.*
655 2022;11(13).
- 656 28. Kim R, Hashimoto A, Markosyan N, et al. Ferroptosis of tumour neutrophils causes immune
657 suppression in cancer. *Nature.* 2022;612(7939):338-346.
- 658 29. Bayir H, Dixon SJ, Tyurina YY, Kellum JA, Kagan VE. Ferroptotic mechanisms and therapeutic targeting
659 of iron metabolism and lipid peroxidation in the kidney. *Nat Rev Nephrol.* 2023;19(5):315-336.
- 660 30. Kristjansson RP, Benonisdottir S, Davidsson OB, et al. A loss-of-function variant in ALOX15 protects
661 against nasal polyps and chronic rhinosinusitis. *Nat Genet.* 2019;51(2):267-276.
- 662 31. Du S, Zeng F, Deng G. Tumor neutrophils ferroptosis: a targetable immunosuppressive mechanism
663 for cancer immunotherapy. *Signal Transduct Target Ther.* 2023;8(1):77.
- 664 32. Mihalj H, Butkovic J, Tokic S, et al. Expression of Oxidative Stress and Inflammation-Related Genes
665 in Nasal Mucosa and Nasal Polyps from Patients with Chronic Rhinosinusitis. *Int J Mol Sci.*

- 666 2022;23(10).
- 667 33. Tai J, Shin JM, Park J, Han M, Kim TH. Oxidative Stress and Antioxidants in Chronic Rhinosinusitis
668 with Nasal Polyps. *Antioxidants (Basel)*. 2023;12(1).
- 669 34. Tsai YJ, Hsu YT, Ma MC, Wu CK, Luo SD, Wu WB. Transcriptomic Analysis of Genes Associated
670 with Oxidative Stress in Chronic Rhinosinusitis Patients with Nasal Polyps: Identifying Novel Genes
671 Involved in Nasal Polyposis. *Antioxidants (Basel)*. 2022;11(10).
- 672 35. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: developing guidance for clinical trials. *J*
673 *Allergy Clin Immunol*. 2006;118(5 Suppl):S17-61.
- 674 36. van der Veen J, Seys SF, Timmermans M, et al. Real-life study showing uncontrolled rhinosinusitis
675 after sinus surgery in a tertiary referral centre. *Allergy*. 2017;72(2):282-290.
- 676 37. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*.
677 2013;29(1):15-21.
- 678 38. Heinz S, Benner C, Spann N, et al. Simple combinations of lineage-determining transcription
679 factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell*.
680 2010;38(4):576-589.
- 681 39. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq
682 data with DESeq2. *Genome Biol*. 2014;15(12):550.
- 683 40. Tripathi S, Pohl MO, Zhou Y, et al. Meta- and Orthogonal Integration of Influenza "OMICs" Data
684 Defines a Role for UBR4 in Virus Budding. *Cell Host Microbe*. 2015;18(6):723-735.
- 685 41. Hanzelmann S, Castelo R, Guinney J. GSEA: gene set variation analysis for microarray and RNA-
686 seq data. *BMC Bioinformatics*. 2013;14:7.
- 687 42. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods*.
688 2012;9(4):357-359.
- 689 43. Jeon YJ, Jo A, Won J, et al. IL-17C Protects Nasal Epithelium from *Pseudomonas aeruginosa*
690 Infection. *Am J Respir Cell Mol Biol*. 2020;62(1):95-103.
- 691 44. Kim JH, Jang JY, Jang YJ. Human rhinovirus serotypes induces different immune responses. *Virology*
692 *J*. 2021;18(1):232.
- 693 45. Yi X, Chang ML, Zhou ZD, et al. LPS induces SGPP2 to participate metabolic reprogramming in
694 endothelial cells. *Free Radic Biol Med*. 2023.
- 695 46. Khan S, Gaivin R, Abramovich C, Boylan M, Calles J, Schelling JR. Fatty acid transport protein-2
696 regulates glycemic control and diabetic kidney disease progression. *JCI Insight*. 2020;5(15).
- 697 47. Veglia F, Tyurin VA, Blasi M, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer.
698 *Nature*. 2019;569(7754):73-78.
- 699 48. Vianey-Saban C, Fouilhoux A, Vockley J, Acquaviva-Bourdain C, Guffon N. Improving diagnosis of
700 mitochondrial fatty-acid oxidation disorders. *Eur J Hum Genet*. 2023;31(3):265-272.
- 701 49. Nicholas DA, Proctor EA, Agrawal M, et al. Fatty Acid Metabolites Combine with Reduced beta
702 Oxidation to Activate Th17 Inflammation in Human Type 2 Diabetes. *Cell Metab*. 2019;30(3):447-

- 703 461 e445.
- 704 50. Qiu P, Wang H, Zhang M, et al. FATP2-targeted therapies - A role beyond fatty liver disease.
705 *Pharmacol Res.* 2020;161:105228.
- 706 51. Zhang M, Di Martino JS, Bowman RL, et al. Adipocyte-Derived Lipids Mediate Melanoma
707 Progression via FATP Proteins. *Cancer Discov.* 2018;8(8):1006-1025.
- 708 52. Larsen SB, Cowley CJ, Sajjath SM, et al. Establishment, maintenance, and recall of inflammatory
709 memory. *Cell Stem Cell.* 2021;28(10):1758-1774 e1758.
- 710 53. Naik S, Larsen SB, Gomez NC, et al. Inflammatory memory sensitizes skin epithelial stem cells to
711 tissue damage. *Nature.* 2017;550(7677):475-480.
- 712 54. Kang K, Park SH, Chen J, et al. Interferon-gamma Represses M2 Gene Expression in Human
713 Macrophages by Disassembling Enhancers Bound by the Transcription Factor MAF. *Immunity.*
714 2017;47(2):235-250 e234.
- 715 55. Divangahi M, Aaby P, Khader SA, et al. Trained immunity, tolerance, priming and differentiation:
716 distinct immunological processes. *Nat Immunol.* 2021;22(1):2-6.
- 717 56. Tang D, Kroemer G. Peroxisome: the new player in ferroptosis. *Signal Transduct Target Ther.*
718 2020;5(1):273.
- 719 57. Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications.
720 *Cell Res.* 2021;31(2):107-125.
- 721 58. Koppula P, Zhuang L, Gan B. Cytochrome P450 reductase (POR) as a ferroptosis fuel. *Protein Cell.*
722 2021;12(9):675-679.
- 723 59. Du X, Li F, Zhang C, et al. Eosinophil-derived chemokine (hCCL15/23, mCCL6) interacts with CCR1
724 to promote eosinophilic airway inflammation. *Signal Transduct Target Ther.* 2021;6(1):91.
- 725 60. Buchheit KM, Dwyer DF, Ordovas-Montanes J, et al. IL-5Ralpha marks nasal polyp IgG4- and IgE-
726 expressing cells in aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol.*
727 2020;145(6):1574-1584.
- 728 61. Heredero-Jung DH, Elena-Perez S, Garcia-Sanchez A, et al. Interleukin 5 Receptor Subunit Alpha
729 Expression as a Potential Biomarker in Patients with Nasal Polyposis. *Biomedicines.* 2023;11(7).
- 730 62. Zhu M, Gao X, Zhu Z, Hu X, Zhou H, Liu J. The roles of nasal nitric oxide in diagnosis and endotypes
731 of chronic rhinosinusitis with nasal polyps. *J Otolaryngol Head Neck Surg.* 2020;49(1):68.
- 732 63. Li YY, Li CW, Chao SS, et al. Impairment of cilia architecture and ciliogenesis in hyperplastic nasal
733 epithelium from nasal polyps. *J Allergy Clin Immunol.* 2014;134(6):1282-1292.
- 734 64. Succar EF, Li P, Ely KA, Chowdhury NI, Chandra RK, Turner JH. Neutrophils are underrecognized
735 contributors to inflammatory burden and quality of life in chronic rhinosinusitis. *Allergy.*
736 2020;75(3):713-716.
- 737 65. Tliba O, Panettieri RA, Jr. Paucigranulocytic asthma: Uncoupling of airway obstruction from
738 inflammation. *J Allergy Clin Immunol.* 2019;143(4):1287-1294.
- 739 66. Huang GJ, Liu HB. Identification and validation of ferroptosis-related genes for chronic

- 740 rhinosinusitis with nasal polyps. *Eur Arch Otorhinolaryngol.* 2023;280(3):1501-1508.
- 741 67. Ma Y, Wei Y, Liu X, et al. Metabolomics analysis of metabolic patterns in chronic rhinosinusitis with
742 nasal polyps. *Allergy.* 2022;77(2):653-656.
- 743 68. Chen CL, Ma J, Lu RY, et al. Perturbated glucose metabolism augments epithelial cell
744 proinflammatory function in chronic rhinosinusitis. *J Allergy Clin Immunol.* 2023;151(4):991-1004
745 e1020.
- 746 69. Li JX, Wang ZZ, Zhai GT, et al. Untargeted metabolomic profiling identifies disease-specific and
747 outcome-related signatures in chronic rhinosinusitis. *J Allergy Clin Immunol.* 2022;150(3):727-735
748 e726.
- 749 70. Okano M, Fujiwara T, Yamamoto M, et al. Role of prostaglandin D2 and E2 terminal synthases in
750 chronic rhinosinusitis. *Clin Exp Allergy.* 2006;36(8):1028-1038.
- 751 71. Gazi L, Gyles S, Rose J, et al. Delta12-prostaglandin D2 is a potent and selective CRTH2 receptor
752 agonist and causes activation of human eosinophils and Th2 lymphocytes. *Prostaglandins Other
753 Lipid Mediat.* 2005;75(1-4):153-167.
- 754 72. Jung HJ, Zhang YL, Kim DK, Rhee CS, Kim DY. The Role of NF-kappaB in Chronic Rhinosinusitis
755 With Nasal Polyps. *Allergy Asthma Immunol Res.* 2019;11(6):806-817.
- 756 73. Kimura Y, Yanagida T, Onda A, Tsukui D, Hosoyamada M, Kono H. Soluble Uric Acid Promotes
757 Atherosclerosis via AMPK (AMP-Activated Protein Kinase)-Mediated Inflammation. *Arterioscler
758 Thromb Vasc Biol.* 2020;40(3):570-582.
- 759 74. Chen Y, Yan Q, Lv M, et al. Involvement of FATP2-mediated tubular lipid metabolic reprogramming
760 in renal fibrogenesis. *Cell Death Dis.* 2020;11(11):994.
- 761
- 762

763 **Table 1. Demographics and clinical characteristics of subjects**

	Control	CRSwNP
RT-qPCR / comparison of severity score	20	20
Age (y), mean ± SD	38.1 ± 52.1	52.1 ± 12.9 [‡]
Male, n (%)	17 (85)	18 (90)
Asthma, n (%)	0	4 (20) [§]
Atopic, n (%)	13 (65)	7 (35)
SNOT-22, mean ± SD	39.5 ± 17.5	42.1 ± 21.4
Lund-Mackay CT score, mean ± SD	0	18.8 ± 4.5
Lund-Kennedy endoscopic score, mean ± SD	0	9.7 ± 2.9
Nasal polyp score, mean ± SD	0	0.5 ± 2.2
Polyp grade, mean ± SD	0	3.7 ± 1.6
Immunofluorescence staining	3	16
Age (y), mean ± SD	54.3 ± 8.3	53.9 ± 12.5
Male, n (%)	2 (66.7)	14 (87.5)
Asthma, n (%)	0	3 (18.8)
Atopic, n (%)	0	5 (31.3)
SNOT-22, mean ± SD	8.7 ± 6.8	42.3 ± 21.1 [‡]
Lund-Mackay CT score, mean ± SD	0	19.3 ± 4.3 [‡]
Lund-Kennedy endoscopic score, mean ± SD	0	9.8 ± 2.8 [‡]
Nasal polyp score, mean ± SD	0	5.1 ± 2.4 [‡]
Polyp grade, mean ± SD	0	3.8 ± 1.7 [‡]
Oil-red O staining	3	7
Age (y), mean ± SD	61.7 ± 17.2	53.6 ± 20.8
Male, n (%)	1 (33.3)	5 (71.4)
Asthma, n (%)	0	2 (28.6)
Atopic, n (%)	0	4 (57.1)
SNOT-22, mean ± SD	3.7 ± 4.7	38.9 ± 21.9 [‡]
Lund-Mackay CT score, mean ± SD	0	16.9 ± 5.3 [‡]

Lund-Kennedy endoscopic score, mean \pm SD	0	9.7 \pm 2.4 [‡]
Nasal polyp score, mean \pm SD	0	3.7 \pm 1.8 [‡]
Polyp grade, mean \pm SD	0	2.7 \pm 0.9 [‡]
Lipofermata treatment	4	4
Age (y), mean \pm SD	37.5 \pm 10.3	44.25 \pm 12.5
Male, n (%)	3 (75)	4 (100)
Asthma, n (%)	0	0
Atopic, n (%)	2 (50)	0
SNOT-22, mean \pm SD	14.8 \pm 17.0	47.3 \pm 34.4
Lund-Mackay CT score, mean \pm SD	0	15.5 \pm 4.8 [‡]
Lund-Kennedy endoscopic score, mean \pm SD	0	8.8 \pm 4.8 [‡]
Nasal polyp score, mean \pm SD	0	8.8 \pm 3.2 [‡]
Polyp grade, mean \pm SD	0	3.5 \pm 1.9 [‡]

764 ‡ P < 0.05, Mann-Whitney U test

765 §, P < 0.05, chi-square test

766 SNOT, Sino-nasal outcome test

767

768 **Table 2. Primers for mRNA expression**

Target Gene		sequence (5'-3')
<i>GAPDH</i>	Forward	GACCCCTTCATTGACCTC
	Reverse	GCTAAGCAGTTGGTGGTG
<i>SLC27A2</i>	Forward	TACTCTTGCCTTGCGGACTAA
	Reverse	CCGAAGCAGTTCACCGATATAC
<i>ALOX15</i>	Forward	TGGAAGGACGGGTTAATTCTGA
	Reverse	GCGAAACCTCAAAGTCAACTCT
<i>FOXJ1</i>	Forward	GCCTCCCTACTCGTATGCCA
	Reverse	GCCGACAGGGTGATCTTGG
<i>TP73</i>	Forward	CGGGCCATGCCTGTTTACA
	Reverse	TGTCCTTCGTTGAAGTCCCTC

769

770 **Figure Legends**

771

772 **Figure 1. Transcriptomic profiling of the nasal polyp cellular microenvironment**

773 (A) Schematic representation of the transcriptome profiling approach incorporating
774 dataset GSE136825, comparing IT tissues from healthy controls (n = 28) to NP tissues
775 from CRSwNP patients (n = 42). Dataset HRA000772 differentiates NP tissues of
776 nECRSwNP patients (n = 5) from those with ECRSwNP (n = 6). Diagrams were produced
777 using BioRender (<https://biorender.com/>). (B) Heatmap displaying the expression
778 patterns of cell-type specific gene sets among upregulated DEGs in nasal polyp tissues,
779 with values represented as z-scores (left). Gene ontology (GO) annotations for the marker
780 gene sets associated with each distinct cell type are shown on the right. (C) Heatmap
781 illustrating the enriched GO terms of lipid metabolic process-related genes upregulated
782 in CRSwNP. (D) Module scores for lipid metabolic processes across individual cells are
783 visualized on UMAP (left) and in a violin plot (right). Error bars represent mean values \pm
784 SEM. P-values in Figure (F) were determined using the Wilcoxon signed-rank test: * P <
785 0.05, ** P < 0.01, *** P < 0.001.

786

787 **Figure 2. Enhanced lipid peroxidation in the nasal polyp epithelium of CRSwNP** 788 **patients**

789 (A) Venn diagram depicting the overlap between upregulated lipid metabolic process-
790 related genes in CRSwNP and those expressed in the epithelial cells of NP. (B)
791 Expression levels of selected genes in CRSwNP relative to healthy controls, based on
792 data from GSE136825. (C) Dot plot illustrating the specific cell types expressing the
793 candidate genes. Color intensity represents the ratio of expression level in each cell
794 cluster relative to the highest expression level across all clusters. Dot size correlates with
795 the percentage of cells in each cluster expressing the gene. (D) Representative
796 immunofluorescence staining images of C11-BODIPY (red) co-localized with DAPI (blue)
797 in both healthy (n = 3) and CRSwNP samples (n = 16). (E) Quantification of the
798 percentage area stained by C11-BODIPY, analyzed using ImageJ. Error bars represent
799 mean values \pm SEM. P-values were derived from an unpaired t-test. * P < 0.05, ** P <
800 0.01, *** P < 0.001, **** P < 0.0001. Scale bars: 50 μ m and 100 μ m.

801
802 **Figure 3. Enhanced expression of *SLC27A2*/*FATP2* in nasal polyp epithelium**
803 (A) Scatter plot showcasing the disparities in gene expression levels of fatty acid
804 transporter-encoding genes between the CRSwNP and healthy groups based on the
805 GSE136825 dataset. (B) mRNA expression levels of *SLC27A2*, quantified via RT-qPCR
806 and normalized to GAPDH mRNA, comparing CRSwNP (n = 20) and healthy samples (n
807 = 20). (C) UMAP projection of previously published single-cell RNA-seq data (Ordovas-
808 Montanes, Jose et al., 2018) comprising 16,415 individual cells, with color coding by cell
809 identity. On the left is a UMAP representation of 16,415 cells derived from nasal scrapings
810 (n = 9), categorized by cell type. The right displays a UMAP representation color-coded
811 by disease location, covering samples directly scraped from the ethmoid sinus polyp in
812 CRSwNP (7,886 cells, n = 2 CRSwNP-NP), directly scraped from the IT tissue of
813 CRSwNP (2,031 cells, n = 4 CRSwNP-IT), and directly scraped from the IT tissue of a
814 healthy control (6,498 cells; n = 3 Healthy-IT). (D) Gene expression distribution of
815 *SLC27A2* visualized on feature plots. (E) Illustrative IF staining images of
816 *SLC27A2*/*FATP2* (shown in green) combined with DAPI (depicted in blue) for healthy (n
817 = 3) and CRSwNP samples (n = 16). (F) Quantitative assessment of the area stained with
818 anti-*FATP2* using ImageJ software. (G) A representative IGV genome browser track,
819 highlighting the normalized tag density associated with *SLC27A2*. Error bars indicate the
820 mean value \pm SEM. Significance was determined using an unpaired t-test: * P < 0.05, **
821 P < 0.01, *** P < 0.001, **** P < 0.0001. Scale bars are set at 50 μ m and 100 μ m.

822
823 **Figure 4. Unique transcriptomic signatures and enhanced lipid peroxidation in**
824 ***SLC27A2*-positive nasal polyp epithelial cells**

825 (A) UMAP plot displaying 9,148 epithelial cells from 11 individuals (5 patients with
826 nECRSwNP and 6 patients with ECRSwNP) categorized into 7 subsets. (B) UMAP plots
827 depicting *SLC27A2*⁻ and *SLC27A2*⁺ epithelial cells in nasal polyps from 11 patients with
828 CRSwNP. *SLC27A2* expression is color-indicated (left). Violin plot showing the
829 expression levels of *SLC27A2* in *SLC27A2*⁻ and *SLC27A2*⁺ epithelial cells (right). (C)
830 Violin plot illustrating the expression levels of *SLC27A2* across 7 epithelial subsets. (D)
831 Dot plots showcasing representative gene expression levels in both *SLC27A2*⁻ and
832 *SLC27A2*⁺ epithelial cells. (E) Heatmap representing the enriched GO terms of

833 differentially expressed genes (DEGs) between *SLC27A2*⁻ and *SLC27A2*⁺ epithelial
834 cells. Values are $-\log_{10}(P\text{-value})$. (F) Violin plot displaying the expression levels of *ACSL4*,
835 *LPCAT3*, *ALOX15*, and *POR* in *SLC27A2*⁻ and *SLC27A2*⁺ epithelial cells. (G)
836 Representative immunofluorescence (IF) staining of *SLC27A2*/FATP2 (green) and C11-
837 BODIPY (red) merged with DAPI (blue) in healthy tissue (n = 3) and CRSwNP tissue (n
838 = 16). (H) Scatter plot depicting correlations between the percentage area stained by anti-
839 FATP2 and C11-BODIPY. *P*-values and correlation coefficients (*R*) were determined using
840 Spearman correlation analysis. Error bars represent mean values \pm SEM. *P*-values were
841 derived from the Wilcoxon signed-rank test. * *P* < 0.05, ** *P* < 0.01, *** *P* < 0.001. Scale
842 bars: 50 μ m and 100 μ m.

843

844 **Figure 5. Transcriptomic features in CRSwNP with high *SLC27A2* expression**

845 (A) Schematic representation of the classification of CRSwNP patients based on
846 *SLC27A2* expression levels using data from the GSE136825 dataset. Diagrams were
847 created using BioRender (<https://biorender.com/>). (B) Heatmap depicting expression
848 levels of differentially expressed genes (DEGs) (FDR < 0.05; two-fold difference in
849 expression; average FPKM > 2). This analysis incorporates both hierarchical and k-
850 means clustering (k = 3) of 2,317 DEGs among the three groups, based on data from
851 GSE136825. (C) Heatmap of enriched Gene Ontology (GO) terms associated with each
852 of the three clusters. Values are represented as $-\log_{10}(P\text{-value})$. (D) Comparative analysis
853 highlighting the expression levels of select genes from Cluster 1, utilizing data from
854 GSE136825. Error bars indicate mean values \pm SEM. *P*-values were calculated using an
855 unpaired t-test and ordinary one-way ANOVA. * *P* < 0.05, ** *P* < 0.01, *** *P* < 0.001, ****
856 *P* < 0.0001.

857

858 **Figure 6. Association of elevated *SLC27A2* expression with severe CRSwNP**

859 (A) Comparison of clinical severity indicators (Lund-Mackay CT score, Lund-Kennedy
860 endoscopic score, nasal polyp score, and polyp grade) between *SLC27A2*^{Low} CRSwNP
861 and *SLC27A2*^{High} CRSwNP groups. (B) Association of *SLC27A2* expression with
862 *ALOX15*, *FOXJ1*, and *TP73* expression. Datasets GSE136825 (upper panel) and
863 GSE179269 (lower panel) were subjected to Spearman correlation analysis. Correlation

864 coefficients (R) and associated *P*-values are presented. (C) Primary hNECs were cultured
865 using an air–liquid interface (ALI) method and subsequently treated with lipofermata for
866 24 hours. RNA extraction was performed on these cells, followed by RT-qPCR analysis.
867 (D) mRNA expression of *SLC27A2*, *ALOX15*, *FOXJ1*, and *TP73* in ALI-cultured hNECs
868 derived from MT tissue of Healthy (n = 4) and NP tissue of CRSwNP (n = 4) individuals.
869 Cells were treated with or without 2 μ M lipofermata for 24 hours, and mRNA levels were
870 assessed via RT-qPCR, normalized to GAPDH mRNA levels. Error bars represent the
871 mean \pm SEM. Statistical significance was determined using unpaired or paired t-tests. *
872 $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.




Figure 1_Park et al.




Figure 2_Park et al.




Figure 3_Park et al.




Figure 4_Park et al.




Figure 5_Park et al.




Figure 6_Park et al.